Fortunately, there is now an effective treatment available for patients with unresectable, locally advanced or metastatic pheochromocytoma and paraganglioma (PPGL). A recent review in Cancers from Dr.

Based on these results, in 2018 the FDA approved iobenguane I-131 as a treatment for adult and paediatric patients 12 years and older with pheochromocytoma and paraganglioma that are positive for ...

The First International Symposium on Pheochromocytoma ... localization, genetics, and treatment. Measurement of plasma or urinary fractionated metanephrines, the most accurate screening approach ...

Rahway, New Jersey Tuesday, January 28, 2025, 10:00 Hrs [IST] ...

The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental New Drug Application (sNDA) for belzutifan for the treatment of adult and pediatric patients aged 12 years and ...

The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.

The US Food and Drug Administration (FDA) will soon decide on whether to expand the label of MSD’s Welireg (belzutifan) to include its use for the treatment of the rare cancer pheochromocytoma and ...

On January 7, 2025, the FDA granted priority review to the new drug application for sunvozertinib (DZD9008), an oral EGFR ...

Merck & Co (NYSE:MRK) said on Monday that the U.S. Food and Drug Administration (FDA) has granted priority review to its application for expanded use of the oral cancer drug Welireg.

The table below is a review of notable updates that occurred in January 2025 for investigational products in development.

Pheochromocytoma occur in the center of the adrenal gland, whereas paraganglioma occur in nerve tissue in the adrenal glands and near certain blood vessels and nerves. Up to 25% of PPGL cases are ...